2. Apoptosis Metabolic Enzyme/Protease
  3. TNF Receptor E1/E2/E3 Enzyme
  4. C25-140

C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 1358099-18-9

Tamaño Precio Stock Cantidad
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 En stock
Solution
10 mM * 1 mL in DMSO En stock
Solid
1 mg En stock
5 mg En stock
10 mg En stock
25 mg En stock
50 mg En stock
100 mg En stock
200 mg   Obtener un presupuesto  
500 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 26 publication(s) in Google Scholar

C25-140 Related Antibodies

Top Publications Citing Use of Products

    C25-140 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 3;16(1):10866.  [Abstract]

    WT and APIPTG/+ mice (10–12 weeks) were injected with LPS (15 mg/kg, 8 h) alone or with C25-140 (14 mg/kg, three doses at 12 h intervals, last dose 4 h before LPS).

    C25-140 purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Dec 1;13(1):97.  [Abstract]

    Western blotting analyses of the effect of C25-140 (20 mol/L, 0-10 h) on YBX1 stability in ATDC5 cells at the indicated time points. GAPDH was used as the loading control.

    C25-140 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Oct 10;11(41):eadw4153.

    GSIS in human islets treated with DMSO or 1 μM C25-140 for 24 hours and exposed to glucolipotoxicity (GLT; 25 mM glucose + 0.5 mM palmitate) or control (5 mM glucose + BSA) for 48 hours. n = 4 to 5 per group.

    C25-140 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Oct 10;11(41):eadw4153.

    Insulin content in human islets treated with DMSO or 1 μM C25-140 for 24 hours and exposed to GLT or control for 48 hours. n = 4 to 5 per group.

    C25-140 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Oct 10;11(41):eadw4153.

    Flow cytometry quantification of mitophagy flux in β cells from mt-Keima mice fed 15-week RFD or HFD, exposed to DMSO or 1 μM C25-140 for 24 hours. n = 3 per group.

    C25-140 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Oct 10;11(41):eadw4153.

    Flow cytometry quantification of mitophagy flux in human β cells exposed to DMSO or 1 μM C25-140 for 24 hours and exposed to GLT or control for 48 hours.

    Ver todos los productos específicos de isoformas TNF Receptor:

    Ver todas las isoformas
    TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

    • Actividad biológica

    • Pureza y Documentación

    • Referencias

    • Revisión del cliente

    Descripciòn

    C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity[1].

    IC50 & Target

    TRAF6-Ubc13[1]
    In Vitro

    C25-140 dose-dependently impedes TRAF6-Ubc13 interaction[1].
    C25-140 (10-30 μM; 2 hours) effectively reduces TRAF6-mediated ubiquitin chain formation[1].
    C25-140 affects TNFα-induced phosphorylation of IκBα as well as NF-κB-induced target gene expression[1].
    C25-140 efficiently inhibits IL-1β- and TNFα-mediated receptor signaling in the context of cytokine activation[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    C25-140 Related Antibodies

    Western Blot Analysis[1]

    Cell Line: TRAF6WT
    Concentration: 10 μM, 20 μM, 30 μM
    Incubation Time: 2 hours
    Result: Effectively reduced TRAF6-mediated ubiquitin chain formation.
    In Vivo

    C25-140 (~1.5 mg/kg; topically to the shaved back and the right ear; twice daily for 6 days) ameliorates symptoms of autoimmune psoriasis in R 837-induced psoriasis mouse model[1].
    C25-140 (6-14 mg/kg; given i.p.; twice daily for 14 days) shows a dose-dependent improvement of RA disease outcome in Collagen-induced arthritis (CIA) model[1].
    C25-140 (10 mg/kg; i.v.) treatment shows that the Cmax, AUC, t1/2 and Vd are 9.7 μg/mL, 274083 ng min/mL, 80.62 min, and 4.13 L/kg, respectively[1].
    C25-140 (10 mg/kg; p.o.) treatment shows that the Cmax, AUC, t1/2 and Vd are 3.4 μg/mL, 124034 ng min/mL, 127.33 min and 13.3 L/kg, respectively[1].
    C25-140 (10 mg/kg; i.p.) treatment shows that the Cmax, AUC, t1/2 and Vd are 4.2μg/mL, 100000 ng min/mL, 184 min, 25.6 L/kg, respectively[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: R 837-induced psoriasis mouse model (male BALB/c mice)[1]
    Dosage: ~1.5 mg/kg
    Administration: Topically to the shaved back and the right ear; twice daily for 6 days
    Result: Showed a dose-dependent improvement of RA disease outcome.
    Animal Model: Collagen-induced arthritis (CIA) model in DBA1/J mice[1]
    Dosage: 6 mg/kg, 10 mg/kg, 14 mg/kg
    Administration: Given i.p.; twice daily for 14 days
    Result: Ameliorated the arthritic index to almost baseline levels in this efficacy model at doses of 10 and 14 mg/kg. Dose-dependently improved symptoms of RA including inflammation and structural damage.
    Animal Model: BALB/C mice[1]
    Dosage: 10 mg/kg
    Administration: I.v. (Pharmacokinetic Analysis)
    Result: The Cmax, AUC, t1/2 and Vd were 9.7 μg/mL, 274083 ng min/mL, 80.62 min, and 4.13 L/kg, respectively.
    Peso molecular

    457.57

    Fòrmula

    C26H31N7O
    No. CAS
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(N1CCC(CC2=CC=CC=C2)CC1)CCC3=C(C)N(C4=NN5C(C=C4)=NN=C5C)N=C3C
    Envío

    Room temperature in continental US; may vary elsewhere.
    Almacenamiento
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvente y solubilidad
    In Vitro: 

    DMSO : 41.67 mg/mL (91.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1855 mL 10.9273 mL 21.8546 mL
    5 mM 0.4371 mL 2.1855 mL 4.3709 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Calculadora de molaridad

    • Calculadora de dilución

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.55 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (4.55 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Pureza y Documentación

    Purity: 99.92%

    SDS (393 KB)

    COA (249 KB) HNMR (269 KB) LCMS (93 KB)

    Instrucciones de manejo (2659 KB)
    Referencias

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1855 mL 10.9273 mL 21.8546 mL 54.6364 mL
    5 mM 0.4371 mL 2.1855 mL 4.3709 mL 10.9273 mL
    10 mM 0.2185 mL 1.0927 mL 2.1855 mL 5.4636 mL
    15 mM 0.1457 mL 0.7285 mL 1.4570 mL 3.6424 mL
    20 mM 0.1093 mL 0.5464 mL 1.0927 mL 2.7318 mL
    25 mM 0.0874 mL 0.4371 mL 0.8742 mL 2.1855 mL
    30 mM 0.0728 mL 0.3642 mL 0.7285 mL 1.8212 mL
    40 mM 0.0546 mL 0.2732 mL 0.5464 mL 1.3659 mL
    50 mM 0.0437 mL 0.2185 mL 0.4371 mL 1.0927 mL
    60 mM 0.0364 mL 0.1821 mL 0.3642 mL 0.9106 mL
    80 mM 0.0273 mL 0.1366 mL 0.2732 mL 0.6830 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    C25-140 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    C25-1401358099-18-9TNF ReceptorE1/E2/E3 EnzymeTumor Necrosis Factor ReceptorTNFRE1 activating enzymeE2 conjugating enzymeE3 ligating enzymeUbiquitin activating enzymeUbiquitin conjugating enzymeUbiquitin ligaseInhibitorinhibitorinhibit

    Productos vistos recientemente:

    Consulta en línea

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Requested Quantity *

    Nombre del solicitante *

    		 

    Saludo

    Direcciòn del E-mail *

    		 

    Número de teléfono *

    Department

    		 

    Nombre de la Organizaciòn *

    City

    Provincia

    Country or Region *

    		      

    Observaciones

    Consulta para venta a granel

    Inquiry Information

    Nombre del producto:
    C25-140
    Cat. No.:
    HY-120934
    Cantidad:
    MCE Japan Authorized Agent:

    Revisión del cliente

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Lot #

    Nombre del solicitante *

    		 

    Direcciòn del E-mail *

    Número de teléfono

    		 

    Department *

    Nombre de la Organizaciòn *

    		 

    Country or Region *

    Observaciones

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.